

Daniel J Brat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2698026/publications.pdf>

Version: 2024-02-01

97
papers

17,388
citations

53751

45
h-index

39638

94
g-index

105
all docs

105
docs citations

105
times ranked

18027
citing authors

#	ARTICLE	IF	CITATIONS
1	Necrotic reshaping of the glioma microenvironment drives disease progression. <i>Acta Neuropathologica</i> , 2022, 143, 291-310.	3.9	23
2	High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13. <i>Acta Neuropathologica</i> , 2022, 143, 403-414.	3.9	13
3	Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 547-574.	1.2	25
4	Aligning the Central Brain Tumor Registry of the United States (CBTRUS) histology groupings with current definitions. <i>Neuro-Oncology Practice</i> , 2022, 9, 317-327.	1.0	3
5	A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis. <i>Acta Neuropathologica Communications</i> , 2022, 10, 47.	2.4	11
6	Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. <i>Neuro-Oncology</i> , 2022, 24, 1989-2000.	0.6	27
7	A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell-of-origin dependent effects of $H3K27M$. <i>Glia</i> , 2022, 70, 1681-1698.	2.5	15
8	Validation of Whole Genome Methylation Profiling Classifier for Central Nervous System Tumors. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 924-934.	1.2	9
9	Abstract 2168: Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment. <i>Cancer Research</i> , 2022, 82, 2168-2168.	0.4	0
10	Abstract 912: A novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of PRC2 target genes. <i>Cancer Research</i> , 2022, 82, 912-912.	0.4	0
11	Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab045.	0.4	4
12	Analysis of morphological characteristics of IDH-mutant/wildtype brain tumors using whole-lesion phenotype analysis. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab088.	0.4	2
13	A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	136
14	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. <i>Neuro-Oncology</i> , 2021, 23, 1231-1251.	0.6	4,534
15	Hypoxia-inducible factors individually facilitate inflammatory myeloid metabolism and inefficient cardiac repair. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	27
16	Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases. <i>Neuro-Oncology Practice</i> , 2021, 8, 662-673.	1.0	6
17	Solitary fibrous tumor of thoracic cavity, extra-thoracic sites and central nervous system: Clinicopathologic features and association with local recurrence and metastasis. <i>Pathology Research and Practice</i> , 2021, 224, 153531.	1.0	5
18	TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas. <i>Clinical Cancer Research</i> , 2021, 27, 5669-5680.	3.2	4

#	ARTICLE	IF	CITATIONS
19	ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. <i>Nature Cancer</i> , 2021, 2, 1372-1386.	5.7	39
20	Data Sets for the Reporting of Tumors of the Central Nervous System: Recommendations From The International Collaboration on Cancer Reporting. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 196-206.	1.2	21
21	Relative survival after diagnosis with a primary brain or other central nervous system tumor in the National Program of Cancer Registries, 2004 to 2014. <i>Neuro-Oncology Practice</i> , 2020, 7, 306-312.	1.0	18
22	Epithelioid Pituicytoma: Expanding the Morphologic Spectrum of a Rare Neoplasm. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 1376-1378.	0.9	0
23	Newly diagnosed enhancing lesions: Steroid initiation may impede diagnosis of lymphoma involving the central nervous system. <i>Journal of Clinical Neuroscience</i> , 2020, 81, 61-64.	0.8	3
24	The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline. <i>Journal of Neuro-Oncology</i> , 2020, 150, 143-164.	1.4	9
25	Is Next-Generation Sequencing Alone Sufficient to Reliably Diagnose Gliomas?. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 763-766.	0.9	6
26	Methods for in vitro modeling of glioma invasion: Choosing tools to meet the need. <i>Glia</i> , 2020, 68, 2173-2191.	2.5	12
27	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. <i>Acta Neuropathologica</i> , 2020, 139, 603-608.	3.9	344
28	The Practical Application of Emerging Technologies Influencing the Diagnosis and Care of Patients With Primary Brain Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e35-e46.	1.8	5
29	cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. <i>Brain Pathology</i> , 2020, 30, 844-856.	2.1	363
30	The Essentials of Molecular Testing in CNS Tumors: What to Order and How to Integrate Results. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 23.	2.0	9
31	The recurrence of the melanotic neuroectodermal tumour of infancy: an unusual presentation of a rare tumour. <i>Ecancermedicalscience</i> , 2020, 14, 1049.	0.6	3
32	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. <i>Neuro-Oncology</i> , 2019, 21, 1498-1508.	0.6	49
33	Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. <i>Oncolmmunology</i> , 2019, 8, e1655360.	2.1	76
34	Surfen-mediated blockade of extratumoral chondroitin sulfate glycosaminoglycans inhibits glioblastoma invasion. <i>FASEB Journal</i> , 2019, 33, 11973-11992.	0.2	27
35	Occupational-like organophosphate exposure disrupts microglia and accelerates deficits in a rat model of Alzheimer's disease. <i>Npj Aging and Mechanisms of Disease</i> , 2019, 5, 3.	4.5	39
36	Chordoma of the corpus callosum: case report. <i>Journal of Neurosurgery</i> , 2019, 131, 1380-1386.	0.9	3

#	ARTICLE	IF	CITATIONS
37	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019, 576, 112-120.	13.7	320
38	The impact of histopathology and NAB2-STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. <i>Acta Neuropathologica</i> , 2019, 137, 307-319.	3.9	44
39	Drak/STK17A Drives Neoplastic Glial Proliferation through Modulation of MRLC Signaling. <i>Cancer Research</i> , 2019, 79, 1085-1097.	0.4	15
40	Effective nuclei segmentation with sparse shape prior and dynamic occlusion constraint for glioblastoma pathology images. <i>Journal of Medical Imaging</i> , 2019, 6, 1.	0.8	2
41	A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. <i>Nature Communications</i> , 2018, 9, 810.	5.8	56
42	Practical Diagnostic Approach to the Presence of Hyphae in Neuropathology Specimens With Three Illustrative Cases. <i>American Journal of Clinical Pathology</i> , 2018, 149, 98-104.	0.4	9
43	Predicting cancer outcomes from histology and genomics using convolutional networks. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E2970-E2979.	3.3	671
44	Meningioma With Tyrosine-Rich Crystalloids: A Case Report and Review of the Literature. <i>International Journal of Surgical Pathology</i> , 2018, 26, 157-160.	0.4	1
45	[¹⁸ F]Fluciclovine PET discrimination between high- and low-grade gliomas. <i>EJNMMI Research</i> , 2018, 8, 67.	1.1	42
46	Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. <i>Npj Precision Oncology</i> , 2018, 2, 24.	2.3	32
47	cIMPACT-NOW update 3: recommended diagnostic criteria for Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV. <i>Acta Neuropathologica</i> , 2018, 136, 805-810.	3.9	599
48	A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 1039-1054.	0.9	105
49	CDK5 Inhibition Resolves PKA/cAMP-Independent Activation of CREB1 Signaling in Glioma Stem Cells. <i>Cell Reports</i> , 2018, 23, 1651-1664.	2.9	34
50	TRIM8 regulates stemness in glioblastoma through PIAS3-STAT3. <i>Molecular Oncology</i> , 2017, 11, 280-294.	2.1	56
51	Genomic Analysis in the Practice of Surgical Neuropathology: The Emory Experience. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 355-365.	1.2	2
52	Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. <i>Acta Neuropathologica</i> , 2017, 133, 1-3.	3.9	120
53	Predicting clinical outcomes from large scale cancer genomic profiles with deep survival models. <i>Scientific Reports</i> , 2017, 7, 11707.	1.6	167
54	Interactive phenotyping of large-scale histology imaging data with HistomicsML. <i>Scientific Reports</i> , 2017, 7, 14588.	1.6	46

#	ARTICLE	IF	CITATIONS
55	cIMPACTâ€œNOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq1 1 0.784314 rgBT /Overlock 10 27, 851-852.	2.1	63
56	PDTB-28. TARGETING MEDULLOBLASTOMA WITH BENZODIAZAPINES DELIVERED USING TUNABLE BIODEGRADABLE HYDROGELS. <i>Neuro-Oncology</i> , 2016, 18, vi156-vi156.	0.6	0
57	Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups. <i>Acta Neuropathologica Communications</i> , 2016, 4, 4.	2.4	26
58	Genomic profiling of lower-grade gliomas uncovers cohesive disease groups: implications for diagnosis and treatment. <i>Chinese Journal of Cancer</i> , 2016, 35, 12.	4.9	19
59	Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. <i>Acta Neuropathologica</i> , 2016, 131, 833-845.	3.9	288
60	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. <i>Cell</i> , 2016, 164, 550-563.	13.5	1,695
61	<i>Drosophila</i> Brat and Human Ortholog TRIM3 Maintain Stem Cell Equilibrium and Suppress Brain Tumorigenesis by Attenuating Notch Nuclear Transport. <i>Cancer Research</i> , 2016, 76, 2443-2452.	0.4	49
62	Defining neoplastic diseases differently: An emerging paradigm from The Cancer Genome Atlas lower-grade gliomas project. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1074333.	0.3	6
63	The Neuropsychiatric Disease-Associated Gene <i>cacna1c</i> Mediates Survival of Young Hippocampal Neurons. <i>ENeuro</i> , 2016, 3, ENEURO.0006-16.2016.	0.9	48
64	Assessing the Effects of Software Platforms on Volumetric Segmentation of Glioblastoma. <i>Journal of Neuroimaging in Psychiatry & Neurology</i> , 2016, 1, 64-72.	0.4	7
65	Wild-type microglia do not reverse pathology in mouse models of Rett syndrome. <i>Nature</i> , 2015, 521, E1-E4.	13.7	159
66	Biomarker-driven diagnosis of diffuse gliomas. <i>Molecular Aspects of Medicine</i> , 2015, 45, 87-96.	2.7	71
67	Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. <i>Genome Research</i> , 2015, 25, 316-327.	2.4	343
68	Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1107-1112.	3.3	137
69	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015, 372, 2481-2498.	13.9	2,582
70	Management of patients with recurrence of diffuse low grade glioma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 609-630.	1.4	50
71	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1â€œAMPK signalling. <i>Nature Cell Biology</i> , 2015, 17, 1484-1496.	4.6	224
72	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 1087-1093.	1.2	13

#	ARTICLE	IF	CITATIONS
73	The Modern Pathologist. Journal of Neuro-Ophthalmology, 2014, 34, 1-2.	0.4	1
74	International Society of Neuropathology's Consortium Guidelines for Nervous System Tumor Classification and Grading. Brain Pathology, 2014, 24, 429-435.	2.1	499
75	The role of neuropathology in the management of progressive glioblastoma. Journal of Neuro-Oncology, 2014, 118, 461-478.	1.4	10
76	Molecular Subtypes of Glioblastoma Are Relevant to Lower Grade Glioma. PLoS ONE, 2014, 9, e91216.	1.1	76
77	Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class. Clinical Cancer Research, 2013, 19, 4951-4960.	3.2	182
78	Cancer Digital Slide Archive: an informatics resource to support integrated in silico analysis of TCGA pathology data. Journal of the American Medical Informatics Association: JAMIA, 2013, 20, 1091-1098.	2.2	149
79	Machine-Based Morphologic Analysis of Glioblastoma Using Whole-Slide Pathology Images Uncovers Clinically Relevant Molecular Correlates. PLoS ONE, 2013, 8, e81049.	1.1	91
80	The Tumor Microenvironment Strongly Impacts Master Transcriptional Regulators and Gene Expression Class of Glioblastoma. American Journal of Pathology, 2012, 180, 2108-2119.	1.9	220
81	Glioblastoma: Biology, Genetics, and Behavior. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 102-107.	1.8	11
82	Digital Pathology: Data-Intensive Frontier in Medical Imaging. Proceedings of the IEEE, 2012, 100, 991-1003.	16.4	39
83	Congenital Glioblastoma: A Clinicopathologic and Genetic Analysis. Brain Pathology, 2007, 17, 276-281.	2.1	51
84	The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-Oncology, 2005, 7, 122-133.	0.6	610
85	Pseudopalisades in Glioblastoma Are Hypoxic, Express Extracellular Matrix Proteases, and Are Formed by an Actively Migrating Cell Population. Cancer Research, 2004, 64, 920-927.	0.4	401
86	Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. Neuro-Oncology, 2004, 6, 96-103.	0.6	55
87	Malignant Glioma Physiology: Cellular Response to Hypoxia and Its Role in Tumor Progression. Annals of Internal Medicine, 2003, 138, 659.	2.0	98
88	Genetic modulation of hypoxia induced gene expression and angiogenesis relevance to brain tumors. Frontiers in Bioscience - Landmark, 2003, 8, d100-116.	3.0	61
89	Infiltrative Astrocytomas With Granular Cell Features (Granular Cell Astrocytomas). American Journal of Surgical Pathology, 2002, 26, 750-757.	2.1	77
90	Genetic and Biologic Progression in Astrocytomas and Their Relation to Angiogenic Dysregulation. Advances in Anatomic Pathology, 2002, 9, 24-36.	2.4	88

#	ARTICLE	IF	CITATIONS
91	Ectopic Cerebellum Presenting as a Suprasellar Mass in Infancy: Implications for Cerebellar Development. <i>Pediatric and Developmental Pathology</i> , 2001, 4, 89-93.	0.5	15
92	Tau-associated neuropathology in ganglion cell tumours increases with patient age but appears unrelated to ApoE genotype. <i>Neuropathology and Applied Neurobiology</i> , 2001, 27, 197-205.	1.8	32
93	Pediatric Chordoid Glioma with Chondroid Metaplasia. <i>Pediatric and Developmental Pathology</i> , 2001, 4, 564-567.	0.5	50
94	Intrasellar Pituicytoma in a Patient With Other Endocrine Neoplasms. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 527-530.	1.2	56
95	Pituicytoma. <i>American Journal of Surgical Pathology</i> , 2000, 24, 362-368.	2.1	207
96	Pediatric Neuroblastic Brain Tumors Containing Abundant Neuropil and True Rosettes. <i>Pediatric and Developmental Pathology</i> , 2000, 3, 346-352.	0.5	128
97	Astroblastoma: Clinicopathologic Features and Chromosomal Abnormalities Defined by Comparative Genomic Hybridization. <i>Brain Pathology</i> , 2000, 10, 342-352.	2.1	127